Our results suggest that high serum CXCL9, CXCL10, and CXCL11 levels may reflect reversible inflammation and that these chemokines are predictive biomarkers of the response to immunosuppressive therapy in ILD with background autoimmunity. Here, CXCL10 is linked to Autoimmunity.